uniQure N.V. (NASDAQ:QURE - Get Free Report) saw unusually-high trading volume on Monday . Approximately 4,935,268 shares traded hands during mid-day trading, an increase of 161% from the previous session's volume of 1,887,982 shares.The stock last traded at $57.97 and had previously closed at $54.31.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on QURE. HC Wainwright reiterated a "buy" rating and set a $70.00 price objective on shares of uniQure in a research note on Wednesday, September 24th. Stifel Nicolaus upped their target price on shares of uniQure from $30.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, September 24th. The Goldman Sachs Group increased their price target on uniQure from $13.00 to $56.00 and gave the stock a "neutral" rating in a report on Thursday. Wells Fargo & Company raised their target price on uniQure from $30.00 to $65.00 and gave the company an "overweight" rating in a report on Thursday. Finally, UBS Group set a $95.00 price objective on shares of uniQure in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $67.17.
View Our Latest Stock Report on uniQure
uniQure Price Performance
The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The company has a market cap of $3.26 billion, a PE ratio of -15.15 and a beta of 0.13. The stock has a fifty day simple moving average of $17.44 and a two-hundred day simple moving average of $14.91.
uniQure (NASDAQ:QURE - Get Free Report) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.20. The company had revenue of $5.26 million for the quarter, compared to analyst estimates of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. On average, equities analysts predict that uniQure N.V. will post -3.75 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, CEO Matthew C. Kapusta sold 226,316 shares of the stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the transaction, the chief executive officer directly owned 651,454 shares in the company, valued at approximately $27,009,282.84. This represents a 25.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Christian Klemt sold 15,000 shares of the stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $55.00, for a total transaction of $825,000.00. Following the transaction, the chief financial officer owned 217,730 shares in the company, valued at approximately $11,975,150. The trade was a 6.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 244,316 shares of company stock worth $10,328,181. Corporate insiders own 4.79% of the company's stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC boosted its position in uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 5,538 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in uniQure in the second quarter worth approximately $117,000. Mraz Amerine & Associates Inc. acquired a new stake in uniQure during the first quarter valued at approximately $106,000. Teacher Retirement System of Texas purchased a new stake in shares of uniQure during the second quarter valued at $151,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of uniQure in the first quarter valued at $152,000. 78.83% of the stock is owned by institutional investors and hedge funds.
uniQure Company Profile
(
Get Free Report)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
